| Size | Price | Stock | Qty |
|---|---|---|---|
| 100g |
|
||
| Other Sizes |
| Targets |
As a synthetic intermediate, Boc-D-leucine does not have a specific biological target. Its role is to serve as a protected D-leucine building block for peptide synthesis. D-Leucine is not naturally incorporated into proteins but has been studied for its potential to inhibit bacterial growth and for its role in modulating immune responses. When incorporated into peptides, the D-configuration can confer resistance to proteases and alter the peptide's three-dimensional structure, potentially improving binding affinity and selectivity for therapeutic targets. The Boc protecting group enables selective coupling at the amino group while leaving the carboxylate available for activation. The compound itself does not interact with enzymes or receptors; its "target" is the peptide bond formation reaction in organic synthesis.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
The in vitro activity of Boc-D-leucine is measured by its coupling efficiency in peptide synthesis. In standard solid-phase or solution-phase peptide coupling, the compound typically achieves >95% yield when activated with reagents such as HATU, HBTU, or DCC, in the presence of a base like DIEA. The coupling reaction is usually carried out at room temperature for 1-4 hours in DMF or dichloromethane. Quality control includes HPLC purity analysis (≥98%) and characterization by NMR and mass spectrometry. The compound does not exhibit any inherent biological activity, such as enzyme inhibition, as it is a protected amino acid not intended for direct biological assays. Its in vitro utility is strictly confined to chemical synthesis as a precursor for more complex peptides. |
| ln Vivo |
In vivo activity is not applicable for Boc-D-leucine because the compound is not intended for administration to living organisms. It is exclusively a research chemical and synthetic intermediate used in laboratory settings for peptide preparation. The compound is not formulated for any route of administration, and no animal efficacy or safety studies have been conducted with the protected amino acid. Any biological activity would only be relevant after the Boc group is removed and the resulting D-leucine is incorporated into a peptide or drug candidate. Its utility lies entirely in the chemical synthesis domain, and it is stored and handled under standard laboratory conditions without consideration for pharmacokinetic or pharmacodynamic properties.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding (non-cellular) experimental workflow for Boc-D-leucine involves standard peptide synthesis and characterization procedures. Typically, the compound (1.0 equivalent) is dissolved in an appropriate solvent such as DMF, and a coupling reagent (e.g., HATU, 1.1 equiv.) and a base (e.g., DIEA, 2 equiv.) are added, followed by the amine component (e.g., resin-bound peptide or amino acid ester). The reaction mixture is stirred at room temperature for 1-4 hours, and progress is monitored by TLC. After completion, the product is isolated by extraction and purified by flash chromatography or recrystallization. Characterization includes ¹H-NMR, ¹³C-NMR, and mass spectrometry to confirm structure. The Boc group can be selectively removed with TFA, and the product can be further characterized for optical purity. The compound's solubility in organic solvents facilitates its use in both solution-phase and solid-phase synthesis.
|
| Cell Assay |
In vitro cell-based experimental workflows are not typically performed with Boc-D-leucine, as the compound is not intended for direct biological activity screening. However, when used as a building block in peptide synthesis, the final deprotected peptide containing D-leucine may be tested in cell-based assays. In such cases, the protected amino acid itself is not used; instead, the peptide is applied to appropriate cell lines (e.g., HEK293, HeLa, or immune cells) at concentrations ranging from 0.1 to 100 µM for 24-72 hours. Assays may include cell viability (MTT), apoptosis (Annexin V), or receptor binding studies (e.g., leucine transporters). The Boc-protected building block is not used in these assays because the protecting group would interfere with cellular uptake and target engagement.
|
| Animal Protocol |
In vivo animal experimental workflows are not applicable for Boc-D-leucine, as it is exclusively a synthetic intermediate, not a drug candidate. There are no established animal models or in vivo protocols associated with the protected amino acid. Any in vivo studies would involve the final deprotected peptide products that incorporate D-leucine residues, rather than the building block itself. The compound is stored under standard conditions (e.g., -20°C) and handled in a fume hood with appropriate personal protective equipment. No animal handling or dosing protocols exist for this compound, and it is not used in veterinary or preclinical research as a standalone agent.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Boc-D-leucine have not been characterized, as the compound is not intended for pharmaceutical use. Being a protected amino acid with a molecular weight of 231.29 g/mol and a predicted LogP of approximately 2.0, it would be expected to have moderate lipophilicity if administered. However, the compound is never administered to living systems, and any pharmacokinetic data would pertain to the deprotected peptide products rather than the building block. The compound is stable under recommended storage conditions (powder at -20°C for up to 3 years) and is not designed for systemic exposure. No ADME studies have been conducted for this compound.
|
| Toxicity/Toxicokinetics |
Toxicological data for Boc-D-leucine are limited because it is not a pharmaceutical agent. Standard safety precautions apply: it may cause skin and eye irritation, and inhalation of dust should be avoided. The compound should be handled in a fume hood with appropriate personal protective equipment, including gloves, safety glasses, and a laboratory coat. No chronic toxicity, carcinogenicity, or reproductive toxicity studies have been conducted, as these are not relevant for a synthetic intermediate. The compound is intended for research use only and is not approved for human or veterinary applications. It is not classified as a hazardous substance under most regulatory frameworks, but standard laboratory chemical safety practices should be followed.
|
| References | |
| Additional Infomation |
Boc-D-leucine is a well-established reagent in peptide chemistry, widely used for the incorporation of D-leucine residues into peptides and pharmaceutical intermediates. D-Leucine has been investigated for its potential to inhibit bacterial growth and its role in modulating immune responses. The Boc protecting group provides stability and ease of removal, making this compound a preferred choice for many synthetic applications. The compound is commercially available with purity ≥98% and is used in both academic and industrial research. It is not a drug and has not undergone clinical trials or received regulatory approval. Its primary applications include the synthesis of protease-resistant peptides, enzyme inhibitors, and antimicrobial agents. The compound is for research use only and is not intended for diagnostic or therapeutic purposes.
|
| Molecular Formula |
C11H21NO4
|
|---|---|
| Molecular Weight |
231.29
|
| Exact Mass |
231.147
|
| CAS # |
16937-99-8
|
| PubChem CID |
637604
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
356.0±25.0 °C at 760 mmHg
|
| Melting Point |
85-87ºC(lit.)
|
| Flash Point |
169.1±23.2 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.461
|
| LogP |
2.51
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
16
|
| Complexity |
255
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)C[C@H](C(=O)O)NC(=O)OC(C)(C)C
|
| InChi Key |
MDXGYYOJGPFFJL-MRVPVSSYSA-N
|
| InChi Code |
InChI=1S/C11H21NO4/c1-7(2)6-8(9(13)14)12-10(15)16-11(3,4)5/h7-8H,6H2,1-5H3,(H,12,15)(H,13,14)/t8-/m1/s1
|
| Chemical Name |
(2R)-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3236 mL | 21.6179 mL | 43.2358 mL | |
| 5 mM | 0.8647 mL | 4.3236 mL | 8.6472 mL | |
| 10 mM | 0.4324 mL | 2.1618 mL | 4.3236 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
